ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.Human vaccines & immunotherapeutics · 2026Observational
- TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response.Human vaccines & immunotherapeutics · 2026Article
- Viral Vaccine Adjuvant Strategies for Shaping Durable Immunity Across the Human Lifespan.Vaccines · 2026Review
- AS01Frontiers in immunology · 2026Article
- [Recommendations for vaccination of adults for respiratory physicians].Pneumologie (Stuttgart, Germany) · 2026Review
- KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E.Frontiers in immunology · 2026Article
- Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination.Reports (MDPI) · 2024Article
- Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.Vaccines · 2023Article
- Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines.NPJ vaccines · 2022Article
- Clinical characteristics of herpes zoster in a pediatric hospital in China from 2007 to 2020.World journal of pediatrics : WJP · 2022Article
- Review
- Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.Human vaccines & immunotherapeutics · 2021Article
- Aging and Options to Halt Declining Immunity to Virus Infections.Frontiers in immunology · 2021Review
- Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine.Open forum infectious diseases · 2020Review
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% against HZ in healthy immunocompetent adults aged ≥50 years after vaccination. In pivotal studies, the efficacy of the new vaccine varied very little with the age of the vaccinee and decreased only by 5-10% in the 3.5 years after immunization. This nonlive vaccine was successfully administered to small cohorts of immunocompromised individuals; initial trials showed efficacy of >60-80% in several such settings. Potential drawbacks include the requirement for 2 vaccine doses separated by 2-6 months, local and systemic reactogenicity that is significantly greater than observed with commonly used vaccines, and the inclusion of a strong adjuvant that has been minimally studied in clinical settings where it might be problematic, such as in people with autoimmune diseases. Postmarketing studies are underway to address some of the drawbacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.